Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000

Rhea-AI Summary

Tryp Therapeutics Inc. announces the closing of its private placement of unsecured convertible debentures to its CEO for AUD$175,000.

Positive

• Tryp Therapeutics Inc. successfully closed its private placement, raising AUD$175,000 for research and development programs and general working capital purposes.

Negative

• None.

KELOWNA, BC / ACCESSWIRE / October 11, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that it has closed its previously announced private placement (the "Private Placement") of unsecured convertible debentures (the "Debentures") to Tryp's newly appointed Chief Executive Officer, Jason Carroll, for aggregate gross proceeds of AUD$175,000.

The proceeds of the Private Placement will be used to advance Tryp's research and development programs and for general working capital purposes.

The securities issued in the Private Placement, including the Common Shares issuable on conversion of the Debentures, will be subject to a hold period of four months and one day from the closing date of the Private Placement in accordance with applicable securities laws.

The Private Placement constitutes a "related party transaction" as such term is defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions("MI 61-101") as Mr. Carroll is a related party of the Company. The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the Private Placement as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transactions, insofar as they involved the related party, exceeded 25% of the Company's market capitalization (as determined under MI 61-101).

About Tryp Therapeutics:

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has initiated a Phase 2a clinical trial for the treatment of Binge Eating Disorder at the University of Florida, where an interim analysis showed an average reduction in binge eating episodes of greater than 80%. The Company is also planning for Phase 2a clinical trials with the University of Michigan for the treatment of fibromyalgia and with Massachusetts General Hospital for the treatment of abdominal pain related to irritable bowel syndrome. An IND for both of these trials has been cleared by the FDA to proceed. Each of the studies are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit is demonstrated, subsequent studies are expected to utilize TRP-8803 (IV-infused psilocin), which has the potential to further improve efficacy, safety and patient experience. For more information, please visit www.tryptherapeutics.com.

Investor & Media Contact

Peter Molloy
Chief Business Officer
Tryp Therapeutics
pmolloy@tryptherapeutics.com

Forward-Looking Information

Certain information in this news release, including statements relating to the anticipated closing date of the Private Placement, constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Tryp Therapeutics Inc.

View source version on accesswire.com:
https://www.accesswire.com/791929/tryp-therapeutics-announces-closing-of-private-placement-of-unsecured-convertible-debentures-for-gross-proceeds-of-aud175000

FAQ

What is the purpose of the private placement?

The proceeds of the private placement will be used for research and development programs and general working capital purposes.

Who participated in the private placement?

Tryp's newly appointed CEO, Jason Carroll, participated in the private placement.

What is the hold period for the securities issued in the private placement?

The securities issued, including the Common Shares, will be subject to a hold period of four months and one day.

Is the private placement considered a related party transaction?

Yes, the private placement is considered a related party transaction as the CEO, Jason Carroll, is a related party of the company.

Did the company comply with the valuation and approval requirements for related party participation?

Yes, the company relied on exemptions from the formal valuation and minority shareholder approval requirements in accordance with applicable securities laws.